Head of R&D Portfolio & Project Management
Illumina
Head of R&D Portfolio & Project Management
Illumina
Develops sequencing platforms and consumables
The Head of R&D Portfolio & Project Management Office (PMO) is accountable for execution excellence across a complex and evolving R&D portfolio. Reporting into the Senior Director of R&D Strategy & Portfolio, this role leads and advances best‑in‑class portfolio, program, and project management capabilities to enable disciplined delivery, predictable outcomes, and transparent execution across R&D.
This leader owns the design, deployment, and continuous improvement of scalable PMO practices, including delivery standards, governance models, and enabling tools. In close partnership with R&D Strategy & Portfolio, the role translates portfolio priorities into integrated execution plans, sequencing, and delivery insights that support effective trade‑offs and decision‑making. This role also builds and sustains strong PMO talent to support increasingly complex, cross‑functional R&D initiatives.
Key Responsibilities:
Core Competencies
Qualifications:
#LI-HYBRID
The estimated base salary range for the Head of R&D Portfolio & Project Management role based in the United States of America is: $205,100 - $307,700. Should the level or location of the role change during the hiring process, the applicable base pay range may be updated accordingly. The range reflects long‑term growth in the role; therefore, most candidates are hired between the minimum and middle of the range. Placement depends on experience, skills, location, and internal equity. Additionally, all employees are eligible for one of our variable cash programs (bonus or commission) and eligible roles may receive equity as part of the compensation package. We offer a wide range of benefits as innovative as our work, including access to genomics sequencing, family planning, health/dental/vision, retirement benefits, and paid time off.Illumina develops and sells integrated sequencing systems and the consumables needed to analyze genetic variation and biological function. Its instruments use sequencing-by-synthesis on flow-cell-based platforms, with specialized reagents and library preparation kits that are consumed per run. The company differentiates itself through a broad end-to-end ecosystem, a large installed base that drives repeat purchases, and strategic acquisitions that expand capabilities into multiomics and clinical applications. Its goal is to advance genomic analysis for research and clinical diagnostics to enable personalized medicine and early cancer detection.
Explore more opportunities at Illumina